CHRS Coherus Oncology, Inc.

Coherus Announces Compelling Interim Clinical Data for Tagmokitug in Esophageal Cancer

Coherus Oncology announced encouraging interim clinical data from its TREGCHECK™ program for its investigational antibody, tagmokitug, in combination with...